Podcasts about Weill Cornell Medicine

The human heart is a tireless biomechanical marvel—an exquisitely engineered pump powered by both mechanical precision and an intrinsic electrical system, beating over 100,000 times a day to sustain life. But like any machine, despite having an electrical mind of its own, it is not infallible—when its rhythm drifts or its mechanics strain, the impact is felt far beyond the chest. From more complex cases like heart failure and detrimental arrhythmias to the more-known feared heart attack caused by high cholesterol, it leads to questions — What can we do to safeguard the health of our heart? What should one do when they experience chest pain? And how do we learn to listen to the heart's warning signs before they become life-altering events?In this episode, we are joined by Dr. Diala Steitieh, MD, a board-certified cardiologist and assistant professor of clinical medicine, focusing on hypertrophic cardiomyopathy and sports cardiology, based in New York City.Dr. Steitieh received her MD from Weill Cornell Medicine in Qatar and completed her Internal Medicine Residency and Cardiovascular Disease Fellowship at NewYork-Presbyterian Hospital/Weill Cornell Medical College. Currently, Dr. Steitieh serves as an Assistant Professor of Clinical Medicine and Principal Investigator of clinical studies at Weill Cornell Medical College and the Director of the Hypertrophic Cardiomyopathy Program in the Division of Cardiology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.Dr. Steitieh has been featured on Yahoo!, SELF Magazine, Qatar Tribune, MSN, TCTMD, and The Peninsula Qatar.Follow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz (Host): Instagram, YouTube

The MI paradox of risk scores, the CELEBRATE trial of a new subcutaneous glycoprotein IIb/IIIA inhibitor (with its funny endpoint), the SURPASS CVOT trial, and the bad story of andexanet alfa are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I What do risk scores mean for individuals? Or perhaps a better question: Is a first MI preventable? Limitations of Screening in Predicting First MI https://www.jacc.org/doi/10.1016/j.jacadv.2025.102361 Sudden Death Due to Cardiac Arrhythmias https://www.nejm.org/doi/abs/10.1056/NEJMra000650 UMC Amsterdam group (EHJ) https://academic.oup.com/eurheartj/article/46/38/3762/8181058 II CELEBRATE Trial CELEBRATE Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268 III SURPASS CVOT Trial Published Aug 01, 2025 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1002781 SURPASS-CVOT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2505928 REWIND Trial 10.1016/S0140-6736(19)31149-3 External Link IV FDA Pulls Andexanet Alfa From the Market ANNEXA 4 https://www.nejm.org/doi/10.1056/NEJMoa1814051 ANNEXA I https://www.nejm.org/doi/full/10.1056/NEJMoa2313040 Richard Buka Tweet https://x.com/richardbuka/status/2001045834050216327?s=20 V Mandrola's Top Cardiovascular Stories of 2025 https://www.medscape.com/viewarticle/mandrolas-top-10-cardiovascular-stories-2025-2025a1000yuh You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Nasser Altorki, thoracic surgeon at Weill Cornell Medicine in New York, and thoracic surgeon and CTSNet Senior Editor Leanne Ashrafian about the 10-year results from the JCOG0802 trial. Chapters 00:00 Intro 02:56 JANS 1, Re-Repair vs Replacement 05:07 JANS 2, Mini Mitral Multicentre RCT 07:01 JANS 3, PERSEVERE Study 08:54 JANS 4, Parietal Pleurectomy vs Pleural Abrasion 11:38 Career Center 12:33 Video 1, Endoscopic Post-Infarction VSD Repair 14:11 Video 2, 3D Dor Procedure & MVR Huge LV Aneurysm 15:19 Video 3, Non-Cardioplegic Myo Protection Robotic 17:16 Nasser Altorki Interview, JCOG 45:16 Upcoming Events 47:20 Closing They discuss key aspects of the trial, including the noninferiority primary endpoint. Dr. Altorki shares his overall thoughts on the trial, and they also examine topics such as pulmonary function, lobar vs sublobar resection, and segmentectomy vs wedge resection. Additionally, they explore secondary primary lung cancer, the importance of thoracic surgeons presenting data to patients, and best practices for segmentectomy to ensure patient safety. They also examine good wedge resection vs bad wedge resection, planning for segmentectomy, and the future of lobectomy and segmentectomy.   Joel also highlights recent JANS articles on the outcomes of re-repair vs replacement after failed primary mitral regurgitation repair, minimally invasive thoracoscopically-guided right minithoracotomy vs conventional sternotomy for mitral valve repair, one-year results of novel aortic arch hybrid prosthesis for repair of acute DeBakey Type I dissection with malperfusion, and a meta-analysis of efficacy and safety of parietal pleurectomy vs pleural abrasion in treating spontaneous pneumothorax.  In addition, Joel explores endoscopic post-infarction VSD repair, 3D video-assisted endoscopic Dor procedure and MVR for post-infarction huge LV aneurysm, and non-cardioplegic myocardial protection for robotic mitral surgery. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Outcomes of Re-Repair Versus Replacement After Failed Primary Mitral Regurgitation Repair: STS Adult Cardiac Surgery Database Analysis  2.) Minimally Invasive Thoracoscopically-Guided Right Minithoracotomy Versus Conventional Sternotomy for Mitral Valve Repair: The UK Mini Mitral Multicentre RCT  3.) One-Year Results of Novel Aortic Arch Hybrid Prosthesis for Repair of Acute DeBakey Type I Dissection With Malperfusion: PERSEVERE Study  4.) A Meta-Analysis of Efficacy and Safety of Parietal Pleurectomy Versus Pleural Abrasion in Treating Spontaneous Pneumothorax  CTSNet Content Mentioned  1.) Endoscopic Post-Infarction VSD Repair  2.) Pushing Surgical Boundaries: 3D Video-Assisted Endoscopic Dor Procedure and MVR for Post-Infarction Huge LV Aneurysm  3.) Non-Cardioplegic Myocardial Protection for Robotic Mitral Surgery  Other Items Mentioned  1.) Instructional Video Competition  2.) 2025 Endoscopic Cardiac Surgeons Club Video Competition  3.) 2025 CTSNet Recruitment Guide   4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

This week on Health Matters, we're sharing an episode of NewYork-Presbyterian's Advances in Care, a show for listeners who want to stay at the forefront of the latest medical innovations and research. On this episode of Advances in Care, host Erin Welsh first hears from Dr. Richard Friedman, a clinical psychiatrist at NewYork-Presbyterian and Director of the Psychopharmacology Clinic at Weill Cornell Medicine. Using his background in psychopharmacology, Dr. Friedman distinguishes between psychedelics and standard antidepressants like SSRIs and SNRIs, explaining the various mechanisms in the brain that respond uniquely to psychedelic compounds. Dr. Friedman also identifies that the challenge of proving efficacy of psychedelic therapy lies in the question of how to design a clinical trial that gives patients a convincing placebo. To learn more about the challenges of trial design, Erin also speaks to Dr. David Hellerstein, a research psychiatrist at NewYork-Presbyterian and Columbia. Dr. Hellerstein contributed to a 2022 trial of synthetic psilocybin in patients with treatment resistant depression. He and his colleagues took a unique approach to dosing patients so that they could better understand the response rates of patients who use psychedelic therapy. The results of that trial underscore an emerging pattern in the field of psychiatry – that while psychedelic therapy has its risks, it's also a promising alternative treatment for countless psychiatric disorders. Dr. Hellerstein also shares more about the future of clinical research on psychedelic therapies to potentially treat a range of mental health disorders.***Dr. Richard Friedman is a professor of clinical psychiatry and is actively involved in clinical research of mood disorders. In particular, he is involved in several ongoing randomized clinical trials of both approved and investigational drugs for the treatment of major depression, chronic depression, and dysthymia.Dr. David J. Hellerstein directs the Depression Evaluation Service at Columbia University Department of Psychiatry, which conducts studies on the medication and psychotherapy treatment of conditions including major depression, chronic depression, and bipolar disorder.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts should change practice? Listen to find out. Some of the abstracts discussed:PARADIGM: https://meetings-api.hematology.org/api/abstract/vmpreview/296881KMT2A Outcomes (MARROW Consortium and Othman, et al.): https://meetings-api.hematology.org/api/abstract/vmpreview/302582 and https://meetings-api.hematology.org/api/abstract/vmpreview/297333CLIA +/- Ven: https://meetings-api.hematology.org/api/abstract/vmpreview/302047FLT3i studies (and MRD): https://meetings-api.hematology.org/api/abstract/vmpreview/295719 and https://meetings-api.hematology.org/api/abstract/vmpreview/302699 and https://meetings-api.hematology.org/api/abstract/vmpreview/291322ALL GIMEMA Trial (blin + ponatinib): https://meetings-api.hematology.org/api/abstract/vmpreview/296532Menin inhibitor data

In this podcast, Mary Sullivan, co-founder of Sweet but Fearless, talks with pioneering OB-GYN, Dr. Marcia Harris, Medical Director of Wellness Restoration Center, who shares her journey through healthcare as the first Black woman to train in obstetrics and gynecology at Weill Cornell Medicine in New York. She reflects on pursuing many interests with a "try it and see" mindset, honoring how far she's come, and following her passion. They also discuss burnout, her shift toward wellness and restoration, and why self-care is survival, not selfishness. This conversation underscores the urgent need to prioritize women's health, personalized care, and putting women back at the center of their own lives. Dr. Marcia A Harris MD trained at the prestigious Weill-Cornell Medical Center, The New York Hospital, after completing medical school at Columbia University College of Physicians and Surgeons.   MORE ABOUT DR. MARCIA HARRIS: Website: The Wellness Restoration Center LinkedIn: Marcia A Harris ABOUT SWEET BUT FEARLESS: Website - Sweet but Fearless LinkedIn - Sweet but Fearless

Dr Manish A Shah from Weill Cornell Medicine in New York, New York, summarizes the treatment landscape and reviews relevant clinical datasets for patients with gastroesophageal cancers. CME information and select publications here.

Dr Manish A Shah from Weill Cornell Medicine in New York, New York, summarizes the treatment landscape and reviews relevant clinical datasets for patients with gastroesophageal cancers. CME information and select publications here.

Dr Manish A Shah from Weill Cornell Medicine in New York, New York, summarizes the treatment landscape and reviews relevant clinical datasets for patients with gastroesophageal cancers. CME information and select publications here.

An elegant study in post-TAVI atrioventricular block, a PSA for my structural colleagues, revascularization in women, and a CTO PCI trial are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I AV Block After TAVR Heart Blocks During vs After TAVR Show Distinct Patterns https://www.medscape.com/viewarticle/heart-blocks-during-vs-after-tavr-show-distinct-patterns-2025a1000ypp Mechanisms Underlying Alterations in Cardiac Conduction After TAVR https://jamanetwork.com/journals/jamacardiology/fullarticle/2842748 II Related PSA Announcement to My Structural Colleagues III Revascularization Strategies in Women with Severe Chronic CAD Women With Chronic Severe CAD Fare Better With CABG vs PCI https://www.medscape.com/viewarticle/women-chronic-severe-cad-fare-better-cabg-vs-pci-2025a1000ygd PCI vs CABG in Women With Chronic CAD https://doi.org/10.1093/eurheartj/ehaf806 PCI vs CABG - Meta-Analysis of 4 RCTs https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02334-5/abstract CABG vs Drug-Eluting Stent Implantation for CAD - Meta-Analysis https://www.jacc.org/doi/10.1016/j.jcin.2016.10.008 RECHARGE trial https://therechargetrial.com/ IV A CTO PCI RCT – But don't get your hopes up Early vs Late-Staged PCI After Subintimal Tracking and Re-entry for CTO https://doi.org/10.1016/j.jacc.2025.09.1598 DECISION CTO trial https://pubmed.ncbi.nlm.nih.gov/30813758/ National Inpatient Sample Database PCI CTO Associated With Higher Mortality https://pubmed.ncbi.nlm.nih.gov/37356643/ V Mandrola's Top 10 Stories You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week on Health Matters, Courtney is joined by Erin Welsh, host of NewYork-Presbyterian's medical research podcast, Advances in Care, to recap an amazing year of health and wellness conversations. They share highlights and discuss the top takeaways from their dozens of conversations with clinicians, researchers – and even a former New York Mets All-Star. This conversation is a great rundown of important health reminders and tips for all of us concerned with staying healthy during the holidays and starting the new year off on the right foot. ___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Less is more after PCI, the TARGET-FIRST trial, a negative blood pressure trial that is actually positive, aspirin vs OAC for bleeding, AEDs, and Factor XI is not dead yet are the topics discussed by John Mandrola, MD, on this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Less is More: TARGET-FIRST TARGET-FIRST Trial https://www.nejm.org/doi/10.1056/NEJMoa2508808 STOPDAPT-2 ACS Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2789701 II A Negative Trial That Is Actually Positive The RETREAT-FRAIL Study https://www.nejm.org/doi/full/10.1056/NEJMoa2508157 III Major Bleeding With Aspirin vs Apixaban Subanalysis of ARTESiA https://jamanetwork.com/journals/jamacardiology/fullarticle/2841075 ARTESiA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2310234 AVERROES Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1007432 IV High Value Interventions – The AED Experts Call for AED Placement on All Commercial Aircraft https://www.medscape.com/viewarticle/experts-call-aed-placement-all-commercial-aircraft-2025a1000xzf In-Flight Sudden Cardiac Arrest and AED Use 10.1016/j.cjca.2025.10.010 External Link V Factor XI Inhibitors – OCEANIC STROKE trial Bayer Press Release on Asundexian https://www.bayer.com/en/us/news-stories/oceanic-stroke You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Claudin 18.2 is a novel biomarker for advanced gastric and gastroesophageal junction cancer. Patients who test positive for claudin 18.2 may be candidates for the monoclonal antibody, zolbetuximab, which directly targets this biomarker. In this episode, CANCER BUZZ speaks with Manish A. Shah, MD, FASCO, director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, about how claudin 18.2 is shaping treatment decisions and some of the clinical trials pursuing more information about the potential for this biomarker. CANCER BUZZ also speaks with Sasha Watson, PharmD, outpatient medical oncology clinical pharmacist at Sylvester Comprehensive Cancer Center, about the importance of engaging the whole multidisciplinary team in biomarker testing for optimal patient outcomes.   "I often talk to my gastroenterologist and ask them to get more than 1 biopsy to make sure that we have enough tissue for now and even in the future." - Manish A. Shah, MD, FASCO Instead of lumping all gastric cancers into one group, we use these biomarkers to split them out... We have more refined and tailored treatments for patients with gastroesophageal adenocarcinoma based on these biomarkers." - Manish A. Shah, MD, FASCO "Nurses in the infusion center are a huge help that we absolutely need, and administering this treatment would be very difficult if we didn't have scaled and experienced nurses here." - Aleksandra (Sasha) Watson, PharmD "What I see is just a lot of patients having hope—some new part of their cancer that we can target with a drug that we previously didn't have any options for." - Aleksandra (Sasha) Watson, PharmD   Guests:               Manish A. Shah, MD, FASCO  Director, Gastrointestinal Oncology Program Weill Cornell Medicine New York, NY Aleksandra (Sasha) Watson, PharmD  Outpatient Medical Oncology Clinical Pharmacist (GI + Sarcoma) Sylvester Comprehensive Cancer Center Miami, FL Resources ACCC Biomarkers Webpage ACCCBuzz Blog: Importance of Biomarker Testing, Patient Goals and Education When Treating Gastric Cancer

Host Shannon Huffman Polson is the founder of The Grit Institute and host of The Grit Factor Podcast, where she helps purpose-driven leaders build grit, resilience, and purpose in their lives and organizations. A former U.S. Army Apache helicopter pilot and one of the first women to fly the Apache in the Army, Shannon brings real-world leadership experience from the military and corporate boardroom to her work as an author, speaker, and leadership educator. She is the author of The Grit Factor: Courage, Resilience, and Leadership in the Most Male-Dominated Organization in the World, which distills lessons from elite leaders across industries and the armed forces. Through The Grit Institute, Shannon combines research, storytelling, and actionable frameworks to help individuals and organizations navigate transitions, overcome challenges, and lead with impact. Her work empowers people to connect with purpose and bring values-based leadership into every facet of life and work. Whether in the cockpit, the classroom, or the boardroom, Shannon champions a mission to cultivate courage, purpose, and authentic leadership for a better world. Guest Bio Dr. Ruth Gotian, Chief Learning Officer and Associate Professor of Education in Anesthesiology at Weill Cornell Medicine, is a globally recognized expert in mentorship and leadership development.  Hailed by Nature, Wall Street Journal, and Columbia University, she was named a top 20 mentor worldwide. Thinkers50 ranked her as the #1 emerging management thinker in 2021, LinkedIn recognized her as a top voice in mentoring in 2023, and she was named a Top 50 Executive Coach in the world in 2024 (Coaches50 list).   A semi-finalist for Forbes 50 Over 50, Dr. Gotian is a prolific contributor to Harvard Business Review, Forbes, and Psychology Today, where she shares insights on 'optimizing success.'  With a focus on the mindset and skill set of peak performers, including Nobel Prize winners, astronauts, Olympic and NBA champions, she's also an award-winning author of The Success Factor and The Financial Times Guide to Mentoring. Summary In this conversation, Shannon Huffman Polson sits down with Dr. Ruth Gotian, a world-renowned expert in leadership, high performance, and success. Together, they explore what truly sets high achievers apart—from astronauts and Olympic athletes to top-performing leaders. Dr. Gotian shares insights from her groundbreaking research on motivation, resilience, and peak performance, revealing practical strategies anyone can apply to excel in their personal and professional life. They also discuss the mindsets that drive exceptional achievement, the habits that separate elite performers from the rest, and how purpose, curiosity, and continuous learning fuel long-term success. Whether you're a leader, creator, or someone striving to improve, this conversation offers actionable wisdom to help you elevate your performance and live with intention. Key Takeaways What Dr. Ruth Gotian has learned from studying the world's highest performers The mindsets and daily habits that drive exceptional success How purpose fuels resilience and long-term motivation The importance of curiosity and continuous learning Practical tools you can start using today to elevate your performance Why high achievers think differently—and how you can too Resources Website: https://ruthgotian.com/ LinkedIn: https://www.linkedin.com/in/rgotian

This week on Health Matters, Courtney sits down with Dr. Braden Kuo, Chief of the Division of Digestive & Liver Diseases at NewYork-Presbyterian and Columbia. Dr. Kuo covers common gut problems during the holiday season, a time of indulgent meals and treats. From bloat to heartburn to travel-related stomach issues, Dr. Kuo is a trove of information and practical tips for navigating holiday festivities with good choices for your gut.  ___ Dr. Braden Kuo is a leading neurogastroenterologist specializing in gastrointestinal motility and the relationship between the brain, nervous system and digestive system. He is the Chief of the Division of Digestive and Liver Diseases at NewYork-Presbyterian/ColumbiaUniversity Irving Medical Center and Columbia University Vagelos College of Physicians andSurgeons. Dr. Kuo received his medical degree from Jefferson Medical College and completed his residency at the University of Texas Southwestern Medical Center before arriving at Massachusetts General Hospital, where he served as director of the Center for Neurointestinal Health. He also completed formal training in clinical research, earning a Master of Science from the Harvard T.H. Chan School of Public Health, and subspecialty training in neurogastroenterology and motility at Mayo Clinic.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

In today's episode, we had the pleasure of speaking with Sarah Rutherford, MD, about the evolving role of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) testing for lymphoma treatment decision-making. Dr Rutherford is an associate professor of clinical medicine in the Division of Hematology/Oncology at Weill Cornell Medicine in New York, New York.  In our exclusive interview, Dr Rutherford discussed the usefulness of ctDNA for guiding patient treatment, clinical trials that are ongoing to determine the best use of this type of assay, how personalized ctDNA testing offers the potential for disease surveillance and effective intervention, key hurdles in the way of widespread implementation of ctDNA testing in clinical practice, and how integration with next-generation sequencing is expected to further tailor treatment strategies.

Dr. Robin Brody is back to tackle a critical gap in clinical training: narcissism and its devastating impact. We cut straight to the core, defining narcissism by its signature trait, entitlement, and exploring the clinical distinctions between grandiose, vulnerable, and malignant subtypes. The episode then dives into the flip side: narcissistic abuse. Learn to spot the confusing dynamics clients face, including performative empathy, denial of reality (often called gaslighting), trauma bonding through intermittent reinforcement, and the predictable cycle of idealization, devaluing, discard, and hoovering. Most crucially, we discuss the "sin" of inadequate provider training and the risk of how applying standard components of evidence-based treatment, like assertiveness skills, can tragically fail or even place survivors in danger.Dr. Robin Brody is an Assistant Professor of Psychiatry (Voluntary) at Weill Cornell Medicine and the founder of Dr. Robin Brody Psychological Services, a private practice specializing in the treatment of occupational trauma, PTSD, and couples therapy, and gender and sexually diverse individuals. Her work is driven by a deep commitment to helping trauma survivors, particularly those facing PTSD and moral injury.Her expertise and demonstrated passion center on treating trauma survivors, particularly those with PTSD and moral injury. In doing so, Dr. Brody has worked with diverse populations of civilians, veterans of all branches and eras, first responders, healthcare workers, and 9/11 survivors and responders across the diagnostic and demographic spectrum. Dr. Brody started and ran an EBP for PTSD program within the World Trade Center Mental Health Program, where she trained and supervised providers in PE and CPT. Before joining Mount Sinai's World Trade Center Mental Health Program, Dr. Brody served on the faculty at Weill Cornell Medicine. In that capacity, Dr. Brody oversaw Weill Cornell's Military Families Wellness Center and worked within the Program for Anxiety and Traumatic Stress Studies (PATSS), where she was a co-investigator on numerous clinical research studies involving the treatment of PTSD, particularly among frontline healthcare workers amidst the COVID-19 pandemic. In all her efforts, Dr. Brody is committed to increasing access to, and training, in evidence-based treatments, especially for PTSD. Dr. Brody's research interests include PTSD treatment innovation and the role of shame, stigma, and identity in trauma recovery.Resources mentioned in this episode: DSM-5 Alternative Model of Personality Disorders It's Not You, Dr. Ramani Durvasula Calls-to-action: Utilize Diagnostic Frameworks: Look into the DSM-5 Alternative Model of Personality Disorders as a useful framework for understanding healthy personality functioning and personality disorders, including narcissism.Obtain additional training on NPD and narcissistic abuseSubscribe to the Practical for Your Practice PodcastSubscribe to The Center for Deployment Psychology Monthly Email Leave us a question or comment on Speakpipe

Listener feedback, huge news in the world of carotid disease with the CREST-2 publication, prasugrel beats ticagrelor again, and a big coffee trial are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Complete Revascularization for Acute MI Meta-analysis  https://doi.org/10.1016/S0140-6736(25)02170-1 II A Sea Change in the Treatment of Carotid Artery Disease — CREST-2 Published ECST-2 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00107-3/fulltext SPACE-2 https://pubmed.ncbi.nlm.nih.gov/36115360/ CREST-2 Trial www.nejm.org/doi/full/10.1056/NEJMoa2508800 CREST Protocol paper https://pmc.ncbi.nlm.nih.gov/articles/PMC5987521/ III Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt PLATO trial https://www.nejm.org/doi/full/10.1056/NEJMoa0904327 Ticagrelor or prasugrel vs clopidogrel in PCI https://eurointervention.pcronline.com/article/ticagrelor-or-prasugrel-versus-clopidogrel-in-patients-undergoing-percutaneous-coronary-intervention-for-chronic-coronary-syndromes ISAR-REACT 5 trial https://www.nejm.org/doi/full/10.1056/NEJMoa1908973 IV Another Coffee and AF study Can Coffee Cut the Risk for Atrial Fibrillation? https://www.medscape.com/viewarticle/can-coffee-cut-risk-atrial-fibrillation-2025a1000w11 A Coffee a Day to Keep the AFib Away? The DECAF Trial Discussed https://www.medscape.com/viewarticle/coffee-day-keep-afib-away-decaf-trial-discussed-2025a1000v5z DECAF trial https://jamanetwork.com/journals/jama/fullarticle/2841253 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week on Health Matters, Courtney talks with Dr. Warren Ng, a psychiatrist at New York Presbyterian and Columbia, and the Community Health Director for the Center for Youth Mental Health at NewYork-Presbyterian. Dr. Ng explains what makes narcissistic traits distinct from narcissistic personality disorders, and offers an in-depth explanation of the symptoms and management strategies for navigating relationships with narcissists, whether colleagues, friends, or family members. ___Dr. Warren Ng is a psychiatrist for children, adolescents, and adults with an interest in HIV, public psychiatry, and family issues. He is the Medical Director of Outpatient Behavioral Health and the Director of clinical services for the Division of Child and Adolescent Psychiatry at Columbia University Irving Medical Center and NewYork-Presbyterian/Morgan Stanley Children's Hospital. He is also the NYP Behavioral Health Service Line Clinical Innovation Officer. He is the President of the American Academy of Child and Adolescent Psychiatry and has been past president of the New York Council on Child and Adolescent Psychiatry. He served on the Assembly and the Council on Children, Adolescents, and Families at the American Psychiatric Association (APA).___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Listener feedback on the PISCES trial, AHA news (including a big PCSK9i trial), beta-blockers post MI, LAAC, and post-AF ablation OAC use are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Why I Believe Fish Oil's Big CV Benefit in Dialysis Patients https://www.medscape.com/viewarticle/why-i-believe-fish-oils-big-cv-benefit-dialysis-patients-2025a1000uzg PISCES trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513032 II PCSK9 Inhibitor News In Global Trial, PCSK9 Inhibitor Provides Major Protection Against First CV Event https://www.medscape.com/viewarticle/global-trial-pcsk9-inhibitor-provides-major-protection-2025a1000uzp VESALIUS-CV trial https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 ODYSSEY trial https://www.nejm.org/doi/full/10.1056/NEJMoa1801174 FOURIER https://www.nejm.org/doi/full/10.1056/NEJMoa1615664 Anish Koka Tweet on LDL-lowering https://x.com/anish_koka/status/1987280506937909326?s=20 III Beta-Blockers After MI and John Cleland Beta-Blockers after MI with normal EF https://www.nejm.org/doi/full/10.1056/NEJMoa2512686 REBOOT-CNIC trial https://www.nejm.org/doi/full/10.1056/NEJMoa2504735 REDUCE AMI trial https://academic.oup.com/ehjcvp/article/9/2/192/6895544?login=false ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204 CAPITAL RCT trial https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199347 Beta-Blockers after MI with mildly reduced EF https://pubmed.ncbi.nlm.nih.gov/40897190/ John Cleland Clinical Outlook https://www.nature.com/articles/s41569-025-01228-w IV Left Atrial Appendage Closure – The CLOSURE-AF trial Percutaneous LAAC in AF Falls Short Again in CLOSURE-AF https://www.medscape.com/viewarticle/percutaneous-left-atrial-appendage-closure-af-falls-short-2025a1000uzu Prague-17 Trial https://www.jacc.org/doi/10.1016/j.jacc.2020.04.067 OPTION trial https://www.nejm.org/doi/full/10.1056/NEJMoa2408308 V Oral AC after AF ablation – the OCEAN Trial Anticoagulation After AF Ablation: The OCEAN Trial Still Leaves Questions https://www.medscape.com/viewarticle/anticoagulation-after-af-ablation-ocean-trial-still-leaves-2025a1000v4t OCEAN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509688 ALONE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2838294 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

In today's episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted an in-depth discussion with Jonathan W. Lee, MD, MSc, on the evolving therapeutic landscape for EGFR-mutant and HER2-positive non–small cell lung cancer (NSCLC). Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Lee is the chief oncology/hematology fellow at Weill Cornell Medicine in New York, New York.

In today's episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with genitourinary (GU) cancer expert Scott T. Tagawa, MD, MS, FACP, FASCO, about the rapidly evolving treatment paradigms for prostate and kidney cancer. Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Tagawa is a professor of medicine and urology at Weill Cornell Medicine, as well as an attending physician at NewYork-Presbyterian – Weill Cornell Medical Center in New York, New York. Their conversation began with a focus on prostate-specific membrane antigen (PSMA)–positive prostate cancer. Dr Tagawa explained that PSMA is a cell surface protein, and that PSMA imaging agents are commonly used to assess biochemical recurrence and perform initial disease staging. He noted that therapy-related adverse effects are often site-specific, including dry mouth/change in taste, and myelosuppression from the radiation payload. For monitoring long-term safety, Dr Tagawa emphasized that renal function must be tracked. Beyond PSMA, other prostate cancer targets include TROP-2, B7-H3, and markers specific to aggressive or neuroendocrine variants, such as DLL3, he reported. In advanced GU cancers, circulating tumor DNA (ctDNA) testing is increasingly important, Dr Tagawa highlighted. In prostate cancer, ctDNA testing is used to assess homologous recombination deficiency (HRD) status and BRCA expression, he said, explaining that evidence for the use of ctDNA testing in GU cancers stems from findings with this type of assay to evaluate minimal residual disease levels in urothelial cancer. He noted that studies show that if patients with urothelial cancer become ctDNA positive within the first year of receiving neoadjuvant chemotherapy, they benefit from treatment with atezolizumab (Tecentriq). Similarly, he stated that patients with previously untreated HRD-positive metastatic prostate cancer also see a progression-free survival benefit when a PARP inhibitor is added to an androgen deprivation therapy/androgen receptor pathway inhibitor backbone. Shifting the conversation to the management of frontline advanced clear cell renal cell carcinoma (RCC), the experts reviewed standard approaches, which involve an immune-oncology (IO) agent plus either a CTLA-4 inhibitor or a VEGF TKI. Tagawa noted that IO/VEGF TKI combinations may be preferred for symptomatic patients needing a rapid response, whereas IO/IO combinations may offer greater potential for treatment cessation. He brought up a key distinction in RCC, which is that re-instituting PD-1/PD-L1 inhibition upon progression in the metastatic setting has generally shown no benefit. Dr Levy brought a broad scope to the GU cancer discussion through his lung cancer expertise, introducing parallels between the treatment paradigms. The interview provided an opportunity to show the importance of creating connections across oncology specialties to bring nuanced perspectives to future advances in clinical research and patient care.

This week on Health Matters, Courtney talks with Dr. Robert Brown, the chief of gastroenterology and hepatology at NewYork-Presbyterian and Weill Cornell Medicine, to discuss the benefits and risks of taking dietary supplements, for our liver and our overall health. Dr. Brown offers tips for deciding which supplements to take, which to avoid, and ways we can optimize our liver health. ___Dr. Robert Brown is an expert in liver diseases, including alcohol-related liver disease, which affects up to 20 percent of the population, chronic hepatitis C infection, which affects an estimated 2.4 million Americans and cirrhosis, a scarring of the liver that is the third most common disease-related cause of death in the United States. He co-founded the Center for Liver Disease and Transplantation at NewYork-Presbyterian/Weill Cornell Medical Center, a joint program with Columbia University Irving Medical Center, in 1998. Dr. Brown will continue as medical director of this program, the largest for liver transplantation in New York City.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Listener feedback on non-culprit PCI in STEMI, a major cardiac result in patients on hemodialysis, news on GLP-1 agonists, a dubious stroke trial, and an AHA preview are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Meta-analysis of MI as a surrogate https://pubmed.ncbi.nlm.nih.gov/34694318/ Compare Acute Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1701067 DANAMI-3–PRIMULTI 10.1016/S0140-6736(15)60648-1 External Link CULPRIT-SHOCK https://www.nejm.org/doi/full/10.1056/NEJMoa1710261   II  Huge Cardiac News for Patients with ESRD PISCES article EMBARGOED Till 1130 AM EST PISCES Trial www.nejm.org/doi/full/10.1056/NEJMoa2513032 REDUCE-IT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1812792 STRENGTH Trial https://jamanetwork.com/journals/jama/fullarticle/2773120 FISH trial https://jamanetwork.com/journals/jama/fullarticle/1150094 III Obesity Agents White House announces deal with Lilly and Novo on GLP-1 drugs https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-shares-rise-trump-obesity-drug-deal-nears-2025-11-06/ Amylin Agonists Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf Eloralintide Phase 2 Study https://doi.org/10.1016/S0140-6736(25)02155-5 GLP-1 Comparisons SURMOUNT-5 Trial https://www.nejm.org/doi/10.1056/NEJMoa2416394 Tirzepatide vs Semaglutide in 10-year CVD Risk Reduction https://doi.org/10.1093/ehjopen/oeaf117 IV A Problematic Trial in Stroke Care LAMP trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2840370 V AHA Preview AHA 2025: Mandrola's Four Trials to Look For https://www.medscape.com/viewarticle/aha-2025-mandrolas-four-trials-look-2025a1000u80 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week on Health Matters, we return to Courtney Allison's conversation with sports cardiologist Dr. Sonia Tolani, who explains how exercise changes the heart. These changes are easy to see in elite athletes, Dr. Tolani gives a behind-the-scenes look at the screening process for athletes to ensure their safety in high-level competition. She also describes how teams can prepare for emergency response, and the life-saving measures that everyone should know when it comes to caring for our hearts. ___Dr. Sonia Tolani received her medical degree with honors from New York University School of Medicine. She completed her internship, medical residency and her fellowship in cardiovascular medicine at Columbia University Medical Center in New York City. Dr. Tolani's areas of expertise include consultative cardiology, preventative medicine and women's heart disease including the treatment of gestational hypertension and preeclampsia. She is board-certified in Internal Medicine, Cardiology and Echocardiography. Dr. Tolani is the co-Director of the Columbia Women's Heart Center, a unique program focusing on providing state of the art treatment and preventative care to women of all ages. In addition to her clinical work, Dr. Tolani is also working on developing digital tools to better educate health care providers about heart disease in women and to improve heart disease awareness in women globally.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Epidurals, Ethics, and Expectations: Talking Risks and Benefits in Obstetric Anesthesia with Joey Bryant-Huppert, MD, Weill Cornell Medicine, New York City, NY

Four pillars of cardiology today, stable coronary artery disease, severe aortic stenosis, the evaluation of chest pain, and best therapies for atrial fibrillation are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Stable CAD Complete vs culprit-only revascularization at time of STEMI iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918 PRAMI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1305520 COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775 FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149 PCI Revascularization Strategies After MI https://www.jacc.org/doi/10.1016/j.jacc.2024.04.051 CULPRIT SHOCK Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1710261 How a Meta-Analysis Can Mislead https://www.sensible-med.com/p/how-a-meta-analysis-can-misleadthe II SEVERE Aortic Senosis 7-Year PARTNER 3 Results – TAVI vs SAVR 7-year results PARTNER 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2509766 PARTNER 3 at 1 year https://www.nejm.org/doi/10.1056/NEJMoa1814052 PARTNER 3 at 5 years https://www.nejm.org/doi/10.1056/NEJMoa2307447 III Functional vs Anatomic Assessment in Suspected CAD 10-year follow-up of PROMISE trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2838118 PROMISE Trial https://www.nejm.org/doi/10.1056/NEJMoa1415516 CCTA vs Functional Stress Test – Meta-Analysis https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2655243 IV ARREST AF ARREST AF trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2840225 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week on Health Matters, Courtney talks with dermatologist Dr. Victoria Perez of NewYork-Presbyterian and Columbia to discuss what cause shingles, how it's treated, and what to expect if you start to see symptoms. ___Dr. Victoria Perez earned her medical degree from Columbia University Vagelos College of Physicians and Surgeons and completed her dermatology residency at NewYork-Presbyterian/Columbia University Irving Medical Center, where she served as chief resident in her final year. Dr. Perez is an active member of the American Academy of Dermatology, the Women's Dermatologic Society, and the Skin of Color Society, where she serves on the Center for Leadership Learning Collaborative. She has authored numerous publications and presented research at both national and local conferences. She is committed to delivering compassionate, evidence-based care to all patients. Dr. Perez provides dermatology services at NewYork-Presbyterian The One, a state-of-the-art center for advanced care with doctors from Columbia in Westchester. NewYork-Presbyterian The One is now accepting appointments and opens in September 2025. The facility will offer adult and pediatric care spanning more than 90 specialties and subspecialties, so patients can find the care they and their families need in one convenient location.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

The PREVENT score in hypertension, GLP-1 mechanism of action in cardiovascular disease, CAD type and statin benefit, and the problem with hospitalization endpoints in HF trials are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Is the PREVENT Calculator Best for Determining CVD Risk? Insights From a Post Hoc Analysis of SPRINT Trial https://www.medscape.com/viewarticle/prevent-calculator-best-determining-cvd-risk-insights-post-2025a1000svo PREVENT Calculator https://doi.org/10.1016/j.jacc.2025.07.037 SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939 II GLP-1 Mechanism of Action in CV Disease Analysis of SELECT Trial 10.1016/S0140-6736(25)01375-3 External Link SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 III Statins and CAD Phenotype on CTA and Outcomes Interactions Between Statin Use, CAD Phenotypes on CTA  https://www.jacc.org/doi/10.1016/j.jcmg.2025.05.018 Statin Use for Primary Prevention of CVD https://jamanetwork.com/journals/jama/fullarticle/2795522 IV HHF Endpoints in Heart Failure Trials The Problem with Hospitalization Endpoints in HF Trials https://onlinelibrary.wiley.com/doi/10.1002/ejhf.70070 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Equipped with a conviction that all of us are leaders in academic medicine, Judy Tung, MD, joins the Faculty Factory Podcast this week to discuss leadership development and so much more. Dr. Tung serves as an Associate Professor of Clinical Medicine at Weill Cornell Medicine in New York City. She is also the Associate Dean of Faculty Development at the School of Medicine. You can see the two articles referenced in this interview here: Putting Traits Associated with Effective Medical Leadership into Action: Support for a Faculty Development Strategy: https://pubmed.ncbi.nlm.nih.gov/39143441/ Enhancing a Faculty Development Program: Identifying and Addressing Leadership Skill Gaps Using an Established Leadership Framework: https://pubmed.ncbi.nlm.nih.gov/40503092/ Learn more: https://facultyfactory.org/judy-tung 

In this episode, Prof. Scott Tagawa (US), a medical oncologist at Weill Cornell Medicine in New York, discusses the results of PSMAddition - a phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

This week on Health Matters, Courtney talks with ophthalmologist Dr. Lisa Park about the best ways to take care of our eye health as we age.  Dr. Park shares tips on ways to protect eye health and preserve vision, as well as some common conditions to watch out for. ___Lisa Park, MD is an Associate Professor of Ophthalmology at Columbia University Medical Center and an Attending Ophthalmologist at New York-Presbyterian Hospital. Dr. Park joined Columbia's Department of Ophthalmology in 2017, and is a well-recognized cataract surgeon with a flourishing practice on Manhattan's west side. She is an expert in the latest surgical techniques including femtosecond-laser assisted cataract surgery and the use of astigmatism and presbyopia correcting intraocular lens implants. Dr. Park lectures nationally and internationally on complex cataract surgery techniques. Her interests include global ophthalmology, and she travels regularly to Guatemala and East Africa to teach and perform humanitarian eye surgery in developing countries, serving on the boards of a number of non-profit organizations dedicated to combating world blindness. ___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Another knock against the antiplatelet/anticoagulant combo, polypills in HF, the physical exam of the future, and the problem of underpowered trials that even Bayesian analyses cannot rescue are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Trends Study https://www.heartrhythmjournal.com/article/S1547-5271(11)00496-6/fulltext II Another knock against the Antiplatelet/Anticoagulation combination “Antiplatelet Plus Oral Anticoagulant Lowers Stroke, Raises Bleeding Risk” https://www.medscape.com/viewarticle/antiplatelet-plus-oral-anticoagulant-lowers-stroke-raises-2025a1000re0 ATIS-NVAF Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2839511 AQUATIC trial https://www.nejm.org/doi/abs/10.1056/NEJMoa2507532 III Polypill for HFrEF A Multilevel Polypill for Patients With HFrEF https://www.jacc.org/doi/10.1016/j.jacadv.2025.102195 IV The Physical Exam of the Future Point-of-Care Ultrasound https://doi.org/10.1016/j.jchf.2025.102707 V More on Underpowered Trials – GA vs Moderate Sedation in IV stroke SEGA Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2839838 Bayesian Analyses of CV Trials https://doi.org/10.1016/j.cjca.2021.03.014 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week on Health Matters, we revisit Courtney Allison's conversation with Dr. Elizabeth Stone, assistant director of transfusion medicine at NewYork-Presbyterian and Columbia. Unprecedented blood shortages mean that the need for donated blood is as critical as ever. Dr. Stone demystifies the process of giving blood, explains blood types, and shares how both the recipient and the donor can benefit from a single donation.___Dr. Elizabeth Stone is Assistant Director of Transfusion Medicine and Cellular Therapy at NYP Columbia University, Medical Director of Clinical Pathology at NYP Westchester Hospital, and Assistant Professor of Pathology and Cell Biology at Columbia University Irving Medical Center. Dr. Stone's research focuses on platelet storage conditions and platelet utilization. With advances in medical care, the demand for platelets continues to increase. She is particularly interested in investigating how platelet storage conditions may affect transfusion in different clinical scenarios and in platelet alloimmunization, with the ultimate goal to improve clinical outcomes for patients requiring platelet transfusions. ___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 use in HFrEF, left atrial posterior wall isolation during AF ablation, peri-device leaks for LAAO, new findings in post-cardiac surgery AF, and imaging before AF ablation are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Listener Feedback HYPERION trial https://www.nejm.org/doi/10.1056/NEJMoa2508170 ZENITH trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160 II GLP1 Use in HFrEF Effects of GLP-1s in Patients With HFrEF https://doi.org/10.1016/j.jchf.2025.102573 FIGHT Study https://jamanetwork.com/journals/jama/fullarticle/2540402 FIGHT Study Post-hoc Analysis https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14862 Substudy of EXSCEL Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.041659 III LA Posterior Wall Isolation Saga Failure of PW Wall Isolation by PFA with Epicardial Mapping https://doi.org/10.1016/j.jacep.2025.08.017 IV Peridevice Leaks After LAAO IMPRESSION LAAC Study https://doi.org/10.1016/j.jacep.2025.08.014 V Post Cardiac Surgery AF Monitoring of New-Onset AF After CABG https://jamanetwork.com/journals/jama/fullarticle/2839710 PACES trial https://clinicaltrials.gov/study/NCT04045665 VI TEE vs ICE Before AF ablation ICE vs TEE Study https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Send us a textIn our Season 11 opening episode, we're bringing you the latest updates from the 2025 ASCO Annual Meeting on metastatic breast cancer. Dr. Ashley Schreier, breast oncologist at Weill Cornell Medicine, breaks down key research and explains what it could mean for people living with MBC.Topics include:Research results for hormone therapy options like camizestrantThe role of ESR1 mutation testingResults from treatment combinations like Enhertu and Perjeta, and Trodelvy and KeytrudaHow to navigate clinical trial accessTips for staying hopeful while exploring treatment optionsWhether you're a patient, caregiver, or advocate, this episode is packed with insights to help you stay informed and empowered.

This week on Health Matters, Courtney talks with nutritionist Gabrielle Gambino and Dr. Jonathan Waitman about the role that sweeteners play in our diet, and how certain options like high fructose corn syrup and cane sugar impact our health. ___Dr. Jonathan Waitman is board certified in Internal Medicine and Clinical Nutrition. He is the course director for the nutrition curriculum and Weill Cornell Medical College. He is also the Medical Director for Specialized Nutrition Support New York Presbyterian Hospital, Weill-Cornell Medical Center. Following completion of his training in Internal Medicine he then went to Memorial Sloan Kettering Cancer Center where he completed a fellowship in clinical nutrition. He has co-authored numerous articles on the subject of obesity. Gabrielle Gambino, MS, RD, CDN, CNSC has undergraduate degrees in Clinical Nutrition and Public Relations from Penn State University. She later went on to complete her Master's in Clinical Nutrition at New York University, and obtained her specialty certification as a Certified Nutrition Support Clinician (CNSC). Gabrielle specializes in nutrition care for patients with advanced heart failure and enjoys finding novel ways to optimize patients' nutritional status before advanced therapies.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Two great stories of translation science leading to beneficial drugs in terrible diseases of the heart and the Sisyphean task of predicting the need for pacing after TAVI are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Sotatercept HYPERION Trial https://www.nejm.org/doi/10.1056/NEJMoa2508170 ZENITH Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160 Evidence report on treatment for PAH https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-on-treatment-for-pulmonary-arterial-hypertension/ PAH Sotatercept Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2503944 II Acoramidis and ATTR Cardiomyopathy ATTRIBUTE-CM Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2305434?logout=true ATTRIBUTE-CM Analysis - Substudy https://www.jacc.org/doi/10.1016/j.jacc.2025.09.013 Tafamadis Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1805689 III Pacing After TAVI Prophylactic pacemaker after TAVI https://www.jacc.org/doi/10.1016/j.jacep.2025.07.028 PROMOTE study https://doi.org/10.1016/j.hrthm.2024.12.019 Evaluation of ESC criteria on RBBB patients undergoing TAVI https://doi.org/10.1016/j.hrthm.2024.11.030 Editorial on Heart Rhythm journal papers https://www.heartrhythmjournal.com/article/S1547-5271(25)00114-6/abstract You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week on Health Matters, Courtney talks with Dr. Vivian Bea, Chief of Breast Surgical Oncology, and Dr. Evelyn Taiwo, a medical oncologist, at New York Presbyterian Brooklyn Methodist Hospital and Weill Cornell Medicine. For Breast Cancer Awareness Month, they discuss why breast cancer is on the rise among younger women, breast cancer risk factors, and the importance of screening. Dr. Bea and Dr. Taiwo also answer common questions about breast cancer, such as what age you can stop screening, and whether common items like deodorant or cell phones increase breast cancer risk.___Vivian Jolley Bea, MD, is Section Chief of Breast Surgical Oncology in the Department of Surgery at NewYork-Presbyterian Brooklyn Methodist Hospital. Dr. Bea received her masters degree in biology from Drexel University and her medical degree from Morehouse School of Medicine. Board certified in general surgery, Dr. Bea is an active member in numerous professional organizations, including the American College of Surgeons, American Society of Breast Surgeons, Society of Surgical Oncologists, and the Society of Black Academic Surgeons. Dr. Bea's areas of interest include breast cancer, benign breast disease, inflammatory breast disease, and high-risk management. She specializes in skin-sparing and nipple sparing mastectomies as well as oncoplastic breast conservation surgery. Dr. Bea is committed to community outreach, research, and eliminating breast cancer disparities.Dr. Evelyn Taiwo, MD, is a medical oncologist at NewYork-Presbyterian Brooklyn Methodist Hospital. She obtained her MD at Temple University School of Medicine in Philadelphia. Following her residency at Boston University Medical Center, she completed a three-year fellowship in hematology and oncology at the University of Texas Southwestern Medical Center in Dallas. Prior to joining Weill Cornell Medicine, Dr. Taiwo served as Assistant Professor of Medicine at the State University of New York, Downstate Medical Center in Brooklyn from July 2011-2019, and as Attending Physician and Site Director for the Hematology-Oncology Fellowship Program at Kings County Hospital. While at Kings County Hospital, she served in a leadership role as Director of the Breast Cancer Clinic, overseeing the operations, research activities, clinical care delivery, and education. As a researcher, Dr. Taiwo has contributed to a number of studies on cancer presentation in urban and minority patient populations.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A bold trial in valvular heart disease, a CV prevention trial whose message is humility, VTE dogma challenged, more news on oral GLP-1 agonists, and a few public service announcements are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I DOUBLE-CHOICE: Minimalist Approach to TAVI May Be as Good as Standard of Care https://www.medscape.com/viewarticle/double-choice-minimalist-approach-tavi-may-be-good-standard-2025a1000pp7 Patient & Physician Perspectives on CV Risk https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011837 II KP Vaccinate Trial KP Vaccinate Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500208 IAMI trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057042 Increasing Flu Vaccinations in Patients With Chronic Disease https://jamanetwork.com/journals/jama/fullarticle/2824956 MI FREEE Trial https://www.nejm.org/doi/full/10.1056/NEJMsa1107913 III Hi PRO Trial Apixaban for Extended Treatment of VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2509426 Recurrent VTE in Patients with Provoked VTE https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/226140 IV Oral GLP-1 Agonists ATTAIN 1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week on Health Matters, we're sharing an episode of NewYork-Presbyterian's Advances in Care, a show for listeners who want to stay at the forefront of the latest medical innovations and research. On this episode of Advances in Care, host Erin Welsh hears from two emergency department chiefs at NewYork-Presbyterian about how they optimize operations in their uniquely high-intensity, high-volume EDs.Dr. Angela Mills, chief of emergency medicine at NewYork-Presbyterian and Columbia, and Dr. Brenna Farmer, chief of emergency medicine at NewYork-Presbyterian Brooklyn Methodist, both lead large medical teams in high-volume, New York City emergency departments. They discuss what makes New York City such a unique environment for emergency care, from its massive population and cultural complexity, to the severity and array of traumas that can come through the ED doors each day. Then, they share stories behind the life-saving care they provide, and explain why the collaborative spirit and excitement of the emergency room keeps them coming back to work every day.Dr. Mills and Dr. Farmer also describe some of the ways that they continuously optimize operations in their departments, including addressing language barriers and providing specialized care for patients with complex cardiac needs. Their goal is to ensure that their staff can navigate the organized intensity of the emergency medicine environment without missing a beat.___Dr. Angela M. Mills is a nationally recognized leader and expert in emergency medicine. She serves as the inaugural chair of the newly designated Department of Emergency Medicine at Columbia University Irving Medical Center and chief of Emergency Medicine Services at NewYork-Presbyterian. Dr. Brenna M. Farmer is Chief of Emergency Medicine at NewYork-Presbyterian Brooklyn Methodist Hospital and vice chair for the Department of Emergency Medicine at Weill Cornell Medicine. She is also an associate professor of clinical emergency medicine at Weill Cornell Medicine. Dr. Farmer is a nationally recognized medical toxicology expert and frequent keynote speaker on quality improvement, patient safety, and medication safety.For more information visit: nyp.org/Advances___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Jonathan Avery, M.D., is the Vice Chair for Addiction Psychiatry, the Stephen P. Tobin and Dr. Arnold M. Cooper Professor in Consultation-Liaison Psychiatry, and the Program Director for the Addiction Psychiatry Fellowship at Weill Cornell Medicine and New York-Presbyterian Hospital.  He is also the medical director for the NBA/NBPA's Anti-Drug Program. Today on the show we discuss: why vaping was sold as “safer” but is actually fueling hidden addiction, how nicotine rewires your brain and makes quitting brutally hard, why most people fail six times before they finally quit, the alarming impact vaping has on kids and developing brains, the truth about the “disease model” of addiction and why personal agency matters, proven strategies to finally break free and rebuild your confidence, what parents can do if they catch their kids vaping, and much more. ⚠ WELLNESS DISCLAIMER ⚠ Please be advised; the topics related to health and mental health in my content are for informational, discussion, and entertainment purposes only. The content is not intended to be a substitute for professional advice, diagnosis, or treatment. Always seek the advice of your health or mental health professional or other qualified health provider with any questions you may have regarding your current condition. Never disregard professional advice or delay in seeking it because of something you have heard from your favorite creator, on social media, or shared within content you've consumed. If you are in crisis or you think you may have an emergency, call your doctor or 911 immediately. If you do not have a health professional who is able to assist you, use these resources to find help: Emergency Medical Services—911 If the situation is potentially life-threatening, get immediate emergency assistance by calling 911, available 24 hours a day. National Suicide Prevention Lifeline, 1-800-273-TALK (8255) or https://suicidepreventionlifeline.org.  SAMHSA addiction and mental health treatment Referral Helpline, 1-877-SAMHSA7 (1-877-726-4727) and https://www.samhsa.gov Learn more about your ad choices. Visit megaphone.fm/adchoices

More trials at ESC, including PARACHUTE HF, DAPA ACT HF-TIMI 68, AMALFI, and a super-interesting modeling study of when to start oral anticoagulants in AF, are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I PARACHUTE HF First Evidence of Treatment Benefit in Chagas Heart Failure https://www.medscape.com/viewarticle/first-evidence-treatment-benefit-chagas-heart-failure-2025a1000oem PARACHUTE-HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021 II SGLT2i Early Initiation — DAPA ACT HF-TIMI 68 Trial Trial Data Support In-Hospital Initiation of SGLT2 Inhibitors for Heart Failure https://www.medscape.com/viewarticle/trial-data-support-hospital-initiation-sglt2-inhibitors-2025a1000o5q DAPA ACT HF-TIMI 68 https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076575 III AMALFI Trial of AF Screening Remote ECG Screening Ups Atrial Fibrillation Detection ‘Modestly' https://www.medscape.com/viewarticle/remote-ecg-screening-ups-atrial-fibrillation-detection-2025a1000myx AMALFI Trial https://jamanetwork.com/journals/jama/article-abstract/2838482 STROKESTOP Trial https://www.thelancet.com/article/S0140-6736(21)01637-8/fulltext LOOP Trial 10.1016/S0140-6736(21)01698-6 External Link IV Finding that Sweet Spot of Stroke Risk Threshold for Starting DOAC therapy Stroke Risk Threshold for non-Vitamin K Antagonist OAC in AF https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012090 Variations in Rates of Stroke Across Patients With AF https://www.ahajournals.org/doi/10.1161/circulationaha.116.024057 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

In this special episode of Health Matters, host Courtney Allison visits Citi Field, home of the New York Mets, to speak with two guests: legendary Mets third baseman David Wright and Dr. Tony Puliafico, a psychologist with NewYork-Presbyterian and Columbia. Together, they discuss the importance of approaching challenges and failures with a growth mindset—in professional sports, at home, at work, at school, and beyond. Through the latest clinical research and stories from David's time with the Mets, they explore healthy habits for approaching failure, connecting to a supportive community, and building resilience for the long term. ___Anthony Puliafico, Ph.D. is a psychologist with the Center for Youth Mental Health at NewYork-Presbyterian. He is also an associate professor of clinical psychology in the Division of Child and Adolescent Psychiatry at Columbia University and serves as Director of the Columbia University Clinic for Anxiety and Related Disorders (CUCARD) -Westchester, an outpatient clinic that specializes in the treatment of anxiety disorders, obsessive-compulsive disorder (OCD) and related disorders in children, adolescents and adults. Dr. Puliafico specializes in the assessment and cognitive-behavioral treatment of anxiety, mood and externalizing disorders. His clinical work and research have focused on the treatment of pediatric OCD, school refusal, and adapting treatments for young children with anxiety.David Wright was a third baseman and captain for the New York Mets from 2004 to 2018. A seven-time All-Star, two-time Gold Glove Award winner, two-time Silver Slugger Award winner, and a member of the 30–30 club, Wright was recently inducted into the Mets Hall of Fame and had his number 5 retired by the team. ___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine. To learn more visit: https://healthmatters.nyp.org Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I New European Valvular Heart Disease Guidelines 2025 ESC/EACTS Guidelines for the management of valvular heart disease  https://doi.org/10.1093/eurheartj/ehaf194 Debate: Does Asymptomatic Aortic Stenosis Warrant Early Intervention? https://exp.medscape.com/debates/does-asymptomatic-aortic-stenosis-warrant-early-intervention/ Surgical Ablation of Atrial Fibrillation during Mitral-Valve Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa1500528 Surgical ablation of atrial fibrillation: a systematic review and meta-analysis https://doi.org/10.1093/europace/eux336 II  New Drug for Resistant HTN Baxdrostat: A 'Game Changer' for Hypertension? https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7 Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2507109 Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension https://www.nejm.org/doi/10.1056/NEJMoa2501440 III HCM News at ESC New Trials Clarify Role of Myosin Inhibitors for Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv MAPLE HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2504654 SEQUOIA HCM https://www.nejm.org/doi/10.1056/NEJMoa2401424 ODYSSEY HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2505927 IV Vericiguat at ESC New Data Said to Support Vericiguat as Standard Therapy for Heart Failurehttps://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9 VICTOR https://doi.org/10.1016/S0140-6736(25)01665-4 VICTORIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915928 An individual participant data analysis of the VICTORIA and VICTOR trials https://doi.org/10.1016/S0140-6736(25)01682-4 V More on Digoxin RATE AF substudy https://doi.org/10.1002/ejhf.70022 Main RATE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2774407 Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis https://doi.org/10.1016/S0140-6736(14)61373-8 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week on Health Matters, Courtney talks with urologic oncologist Dr. Michael Feuerstein of Columbia and NewYork-Presbyterian The One, a new center for advanced care in Westchester, to discuss the importance of screening for prostate cancer. Dr. Feuerstein explains how blood tests work to detect prostate cancer, explores the latest advancements in treatment, and debunks common myths and misunderstandings about prostate health. ___Dr. Michael Feuerstein, MD, MPH, is the chief of urology at NewYork-Presbyterian Westchester and assistant professor in the Department of Urology at Columbia University Vagelos College of Physicians and Surgeons. Dr. Feuerstein is a board-certified urologist with over ten years of experience, specializing in minimally-invasive surgery for prostate, kidney, and bladder cancer. He received his medical degree and completed his urology residency training at Albany Medical Center. He completed a two-year fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center and received a master's degree in public health at the Columbia Mailman School of Public Health. Dr. Feuerstein's research focuses on improving quality of care and quality of life for patients diagnosed with urologic cancers. Dr. Feuerstein provides care at NewYork-Presbyterian The One, a state-of-the-art center for advanced care with doctors from Columbia in Westchester. The facility offers adult and pediatric care spanning more than 90 specialties and subspecialties, so patients can find the care they and their families need in one convenient location.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

The big beta-blocker story from ESC, dual pathway therapy with aspirin and OAC, stopping OAC after successful AF ablation, and DANCAVAS II trial are the topics John Mandrola, MD, discusses on this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback This Week in Cardiology Podcast – August 29 https://www.medscape.com/viewarticle/1002877 II The Big Beta-blocker Story from ESC Beta-Blockers Post-MI: A Clear Clinical Message https://www.medscape.com/viewarticle/beta-blockers-post-mi-clear-clinical-message-2025a1000mz0 REBOOT https://www.nejm.org/doi/full/10.1056/NEJMoa2504735 BETAMI-DANBLOCK https://www.nejm.org/doi/abs/10.1056/NEJMoa2505985 REDUCE AMI https://www.nejm.org/doi/10.1056/NEJMoa2401479 CAPITAL RCT https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199347 Post Hoc Analysis From REBOOT Trial https://eurointervention.pcronline.com/article/effect-of-beta-blocker-withholding-or-withdrawal-after-myocardial-infarction-without-reduced-ejection-fraction-on-ischaemic-events-a-post-hoc-analysis-from-the-reboot-trial Beta-Blockers After MI With Mildly Reduced Ejection Fraction https://doi.org/10.1016/S0140-6736(25)01592-2 CAPRICORN 10.1016/S0140-6736(00)04560-8 External Link BHAT https://jamanetwork.com/journals/jama/fullarticle/370103 ISIS 1 https://pubmed.ncbi.nlm.nih.gov/2873379/ III Aspirin and OAC Combination Clearly Dangerous Aspirin Plus Oral Anticoagulants Raises Mortality, Bleeding https://www.medscape.com/viewarticle/aspirin-plus-oral-anticoagulants-raises-mortality-bleeding-2025a1000nam AQUATIC https://www.nejm.org/doi/full/10.1056/NEJMoa2507532 AFIRE https://www.nejm.org/doi/full/10.1056/NEJMoa1904143 EPIC CAD https://www.nejm.org/doi/10.1056/NEJMoa2407362 OAC-ALONE  https://pubmed.ncbi.nlm.nih.gov/30586700/ IV Stop or Continue OAC after Successful AF Ablation ALONE-AF https://jamanetwork.com/journals/jama/fullarticle/2838294 OCEAN trial protocol https://doi.org/10.1016/j.ahj.2017.12.007 V DANCAVAS II Trial DANCAVAS II https://doi.org/10.1093/eurheartj/ehaf704 DANCAVAS I https://www.nejm.org/doi/full/10.1056/NEJMoa2208681 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

CAC 0 takes a gut punch, ICD therapies cannot be surrogates for benefit, and two important trials from ESC are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I CAC 0 LDL-C and CVD Risk With CAC Score 0 https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf497/8228645 II ICD Therapies Contemporary ICD Benefit https://www.jacc.org/doi/10.1016/j.jacep.2025.06.028 PROFID Trial https://profid-project.eu/profid-ehra-trial/ MADIT-RIT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1211107 Declining Risk of Sudden Death in HF https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 III Digit-HF DIGIT-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415471 Digoxin–Mortality: Comparison in the DIG trial https://academic.oup.com/eurheartj/article/40/40/3336/5520008 IV POTCAST POTCAST trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509542 ESC Preview IV HTN Guidelines New Blood Pressure Guidelines: 4 Things I Like and 2 Concerns  https://www.medscape.com/viewarticle/new-blood-pressure-guidelines-4-thing-i-and-2-concerns-2025a1000m1x You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

John Mandrola discusses conduction system pacing vs standard pacing, withdrawing HF meds when AF is corrected and patient selection in LAAO. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Conduction System Pacing CSPACE trial https://doi.org/10.1016/j.jacc.2025.06.043 BLOCK HF trial https://www.nejm.org/doi/full/10.1056/NEJMoa1210356 BioPace trial https://doi.org/10.1093/europace/euaf029 II  Withdrawing Meds After AF Corrected WITHDRAW AF https://doi.org/10.1093/eurheartj/ehaf563 TRED HF https://pubmed.ncbi.nlm.nih.gov/30429050/ III Patient Selection in Left Atrial Appendage Occlusion Long-Term Outcomes Following LAAO in Medicare Beneficiaries: Outcomes From the National Cardiovascular Data Registry https://www.ahajournals.org/doi/10.1161/JAHA.124.039780 ESC Preview IV HTN Guidelines New Blood Pressure Guidelines: 4 Things I Like and 2 Concerns https://www.medscape.com/viewarticle/new-blood-pressure-guidelines-4-thing-i-and-2-concerns-2025a1000m1x You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Big new hypertension guidelines, ultraprocessed foods, coronary sinus reduction and evidence-based medicine, and more news on pulsed field ablation for atrial fibrillation are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I HTN Guidelines BP Meds Should Begin Promptly, New ACC/AHA Guidelines Say https://www.medscape.com/viewarticle/bp-meds-should-begin-promptly-new-acc-aha-guidelines-say-2025a1000lms Guideline for Management of High Blood Pressure https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356 BPROAD trial https://www.nejm.org/doi/full/10.1056/NEJMoa2412006 Trial Score Framework https://pmc.ncbi.nlm.nih.gov/articles/PMC6459598/ II UltraProcessed Foods AHA statement on Ultraprocessed Foods and Cardiometabolic Health https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001365 III Refractory Angina and the Coronary Sinus Reducer – A Lesson in EBM Coronary Sinus Reducer Shows Promise, With Caveats https://www.medscape.com/viewarticle/coronary-sinus-reducer-shows-promise-caveats-2025a1000l76 Coronary Sinus Reducer — Meta-analysis https://www.jacc.org/doi/10.1016/j.jcin.2025.06.012 COSIRA II Trial https://clinicaltrials.gov/study/NCT05102019 IV Pulsed Field Ablation Still Looking Strong Management of OACs After PFA 10.1016/j.hrthm.2025.03.1952 External Link You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net